---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005600"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:18:56.591503+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences Q2 net loss $1.3M; cash $7.3M; DNase program advancing

## Summary
- Net loss of $1.3M for Q2 2024; R&D expenses flat at $0.9M; G&A up 19.5% to $1.1M on severance.
- Royalty payments from Takeda sublicense of PolyXen platform were $0.7M, up 11.6% YoY.
- Cash balance $7.3M at quarter end; expected to fund operations into clinical development.
- Preclinical studies for DNase oncology platform ongoing; data expected before year end.
- Advancing towards Phase 1 clinical proof-of-concept in pancreatic carcinoma and solid tumors.

## SEC filing metadata
- accession: 0001683168-24-005600
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316824005600/0001683168-24-005600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316824005600/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005600
- JSON: https://secwatch.observer/filing/0001683168-24-005600.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.